Harrow Health/$HROW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harrow Health
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Ticker
$HROW
Sector
Primary listing
Employees
382
Headquarters
Website
Harrow Health Metrics
BasicAdvanced
$1.4B
-
-$0.29
0.41
-
Price and volume
Market cap
$1.4B
Beta
0.41
52-week high
$56.01
52-week low
$20.85
Average daily volume
618K
Financial strength
Current ratio
0.622
Quick ratio
0.213
Long term debt to equity
95.032
Total debt to equity
95.032
Interest coverage (TTM)
0.59%
Profitability
EBITDA (TTM)
31.113
Gross margin (TTM)
74.56%
Net profit margin (TTM)
-4.49%
Operating margin (TTM)
6.44%
Effective tax rate (TTM)
4.61%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
2.81%
Return on equity (TTM)
-19.03%
Valuation
Price to revenue (TTM)
6.039
Price to book
28.42
Price to tangible book (TTM)
28.42
Price to free cash flow (TTM)
-39.71
Free cash flow yield (TTM)
-2.52%
Free cash flow per share (TTM)
-0.961
Growth
Revenue change (TTM)
47.69%
Earnings per share change (TTM)
-70.08%
3-year revenue growth (CAGR)
39.23%
10-year revenue growth (CAGR)
47.98%
3-year earnings per share growth (CAGR)
-31.76%
10-year earnings per share growth (CAGR)
-14.01%
What the Analysts think about Harrow Health
Analyst ratings (Buy, Hold, Sell) for Harrow Health stock.
Harrow Health Financial Performance
Revenues and expenses
Harrow Health Earnings Performance
Company profitability
Harrow Health News
AllArticlesVideos
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
Business Wire·1 month ago
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
Business Wire·2 months ago
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harrow Health stock?
Harrow Health (HROW) has a market cap of $1.4B as of August 22, 2025.
What is the P/E ratio for Harrow Health stock?
The price to earnings (P/E) ratio for Harrow Health (HROW) stock is 0 as of August 22, 2025.
Does Harrow Health stock pay dividends?
No, Harrow Health (HROW) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next Harrow Health dividend payment date?
Harrow Health (HROW) stock does not pay dividends to its shareholders.
What is the beta indicator for Harrow Health?
Harrow Health (HROW) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.